DONOR CHIMERISM IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION

Allogeneic stem cell transplantation (alloHSCT) is effective curative option for a broad range of primary immunodeficiencies (PIDs). Hematopoietic chimerism monitoring in patients with various PIDs and its connection with the outcome of alloHSCT is of great interest. In this study 16 alloHSCT in patients with PIDs were included. Three-year overall survival was 72.2 ± 12.0 %. Full donor chimerism (FDC) was achieved in 13 (81.25 %) patients. Prolonged persistence of mixed chimerism (MC) was observed in 3 (18.75 %) patients. In patients with MC in the peripheral blood, circulating T-cells are completely or predominantly of donor origin, whereas granulocytes are predominantly or completely recipient cells, and chimerism in B-cells differs significantly from 0 % chimerism to FDC. In patients with PIDs, engraftment of individual cell lines (split chimerism) could be observed. In some patients chimerism decreased during the first year after alloHSCT with its subsequent stabilization. Increasing MC is not associated with transplant rejection in PIDs. FDC in patients with PIDs provides restoration of all cell lines participating in the immune response regardless of the diagnosis, but it is associated with more frequent development of «graft-versus-host» disease (GVHD), which is a serious complication of alloHSCT and can lead to treatment-related mortality (TRM). MC/split chimerism, in which the frequency of development of GVHD is less, can also provide the formation of a full immune response and correction of other disease manifestations, but only when replacing defective cell lines according to the diagnosis.

1. Ochs H.D., Hagin D. Primary immunodeficiency disorders: general classification, new molecular insights, and practical approach to diagnosis and treatment. Ann Allergy, Asthma Immunol 2014;112(6):489–95. DOI: 10.1016/j.anai.2014.04.007. PMID: 24860921.

2. EBMT/ESID guidelines for haematopoietic stem cell transplantation for primary immunodeficiencies [Online]. Inborn Errors Working Party (IEWP) 2017. Available from: https://esid.org/content/download/15402/422689/file/ESID%20 EBMT%20HSCT%20Guidelines%20 2017.pdf.

3. Chiesa R., Veys P. Reduced-intensity conditioning for allogeneic stem cell transplant in primary immune deficiencies. Expert Rev Clin Immunol 2012;8(3):255–66. DOI: 10.1586/eci.12.9. PMID: 22390490.

4. Slatter M.A., Rao K., Abd Hamid I.J. et al. Treosulfan and Fludarabine Conditioning for Hematopoietic Stem Cell Transplantation in Children with Primary Immunodeficiency: UK Experience. Biol Blood Marrow Transplant 2018;24(3): 529–36. DOI: 10.1016/j.bbmt. 2017.11.009. PMID: 29155317.

5. Mattsson J., Ringden O., Storb R. Graft Failure after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl 2008;14(1 Suppl 1):165–70. DOI: 10.1016/j.bbmt.2007.10.025. PMID: 18162238.

6. Olsson R., Remberger M., Schaffer M. et al. Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant 2013;48(4):537–43. DOI: 10.1038/bmt.2012.239.PMID: 23222384.

7. Burroughs L., Woolfrey A. Hematopoietic cell transplantation for treatment of primary immune deficiencies. Cell Ther Transplant 2010;2(8). DOI: 10.3205/ctt-2010-en-000077.01. PMID: 21152385.

8. Alizadeh M., Bernard M., Danic B. et al. Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood 2002;99(12):4618–25. DOI: 10.1182/blood.V99.12.4618. PMID: 12036896.

9. Koldehoff M., Steckel N.K., Hlinka M. et al. Quantitative Analysis of Chimerism after Allogeneic Stem Cell Transplantation by Real-Time Polymerase Chain Reaction with Single Nucleotide Polymorphisms, Standard Tandem Repeats, and Y-Chromosome-Specific Sequences. Am J Hematol 2006;81(10):735–46. DOI: 10.1002/ajh.20693.PMID: 16838323.

10. Lavrinenko V.A., Savitskaya T.V., Volochnik E.V. et al. Quantitative analysis of chimerism after allogeneic hematopoietic stem cell transplantation with molecular genetic methods. Onkogematologiya = Oncohematology 2014;9(2):29–36 (In Russ.). DOI: 10.17650/1818-8346-2014-9-2-29-36.

11. Rao K., Amrolia P.J., Jones A. et al. Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen. Blood 2005;105(2):879–85. DOI:10.1182/blood-2004-03-0960. PMID: 15367433.

12. Amrolia P., Gaspar H.B., Hassan A. et al. Non-myeloablative stem cell transplantation for congenital immunodeficiencies. Recent Results Cancer Res 2002;159: 134–42. PMID: 11785837.

13. Hamidieh A.A., Behfar M., Pourpak Z. et al. Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study. Bone Marrow Transplant 2016;51(2):219–26. DOI: 10.1038/bmt.2015.277. PMID: 26595073.

14. Rao K., Adams S., Qasim W. et al. Effect of stem cell source on long-term chimerism and event-free survival in children with primary immunodeficiency disorders after fludarabine and melphalan conditioning regimen. J Allergy Clin Immunol 2016;138(4), 1152–60. DOI: 10.1016/j.jaci.2016.01.053. PMID: 27241891.

15. Dvorak C.C., Hassan A., Slatter M.A. et al. Comparison of outcomes of hematopoietic stem cell transplantation without chemotherapy conditioning by using matched sibling and unrelated donors for treatment of severe combined immunodeficiency. J Allergy Clin Immunol 2014;134(4):935–43. e15. DOI: 10.1016/j.jaci.2014.06.021. PMID: 25109802.

16. Scarselli A., Di Cesare S., Capponi C. et al. Longitudinal Evaluation of Immune Reconstitution and B-cell Function After Hematopoietic Cell Transplantation for Primary Immunodeficiency. J Clin Immunol 2015;35(4):373–83. DOI: 10.1007/s10875-015-0154-4. PMID: 25875698.

17. Buckley R.H. Transplantation of hematopoietic stem cells in human severe combined immunodeficiency: longterm outcomes. Immunol Res 2010; 49(1–3):25–43. DOI: 10.1007/s12026-010-8191-9. PMID: 21116871.

18. Cavazzana-Calvo M., Carlier F., Le Deist F. et al. Long-term T-cell reconstitution after hematopoietic stemcell transplantation in primary T-cellimmunodeficient patients is associated with myeloid chimerism and possibly the primary disease phenotype. Blood 2007;109(10):4575–81. DOI: 10.1182/blood-2006-07-029090. PMID: 17272510.

19. Massaad M.J., Ramesh N., Geha R.S. Wiskott-Aldrich syndrome: a comprehensive review. Ann N Y Acad Sci 2013;1285:26–43. DOI: 10.1111/nyas.12049. PMID: 23527602.

20. Moratto D., Giliani S., Bonfim C. et al. Long-term outcome and lineage-specific chimerism in 194 patients with WiskottAldrich syndrome treated by hematopoietic cell transplantation in the period 1980–2009: an international collaborative study. Blood 2011;118(6):1675–84. DOI: 10.1182/blood-2010-11-319376. PMID: 21659547.

21. Ozsahin H., Cavazzana-Calvo M., Notarangelo L.D. et al. Long-term outcome following hematopoietic stemcell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. Blood 2008;111(1):439–45. DOI: 10.1182/blood-2007-03-076679. PMID: 17901250.

22. Hassan A., Lee P., Maggina P., Xu J.H. Host natural killer immunity is a key indicator of permissiveness for donor cell engraftment in patients with severe combined immunodeficiency. J Allergy Clin Immunol 2014;133(6):1660–66. DOI: 10.1016/j.jaci.2014.02.042.PMID: 24794685.

23. Mazzolari E., Forino C., Guerci S. et al. Long-term immune reconstitution and clinical outcome after stem cell transplantation for severe T-cell immunodeficiency. J Allergy Clin Immunol 2007;120(4):892–9. DOI: 10.1016/j.jaci.2007.08.007.PMID: 17825895.

24. Sarzotti-Kelsoe M., Win C.M., Parrott R.E. et al. Thymic output, T cell diversity and T cell function in long-term human SCID chimeras. Blood 2009;114(7):1445–53. DOI: 10.1182/blood-2009-01-199323. PMID: 19433858.

25. Buckley R.H. B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review. J Allergy Clin Immunol 2010;125(4),790–7. DOI: 10.1016/j.jaci.2010.02.012. PMID: 20371393.

26. Haddad E., Leroy S., Buckley R.H. B-cell reconstitution for SCID: Should a conditioning regimen be used in SCID treatment? J Allergy Clin Immunol 2013;131(4):994–1000. DOI: 10.1016/j.jaci.2013.01.047. PMID: 23465660.

27. Buckley R.H., Win C.M., Moser B.K. et al. Post-transplantation B cell function in different molecular types of SCID. J Clin Immunol 2013;33(1), 96–110. DOI: 10.1007/s10875-012-9797-6. PMID: 23001410.

28. Locatelli F., Lucarelli B., Merli P. Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Pharmacother 2014;15(1):23–36. DOI: 10.1517/14656566.2014.852537. PMID: 24156789.